Skip to main content
JIN YANG PHARMACEUTICAL. CO., LTD logo

JIN YANG PHARMACEUTICAL. CO., LTD — Investor Relations & Filings

Ticker · 007370 ISIN · KR7007370000 KO Manufacturing
Open in API
Filings indexed 210 across all filing types
Latest filing 2023-12-15 Notice of Dividend Amou…
Country KR South Korea
Listing KO 007370

About JIN YANG PHARMACEUTICAL. CO., LTD

https://www.jinyangpharm.com/

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory announcement from Jinyang Pharmaceutical regarding the setting of a record date for shareholder register closure for the purpose of dividend distribution. It explicitly states that this is a notice of the record date and that specific dividend details will be determined later. Since it announces the record date for dividends rather than the final dividend amount or payment, and fits the regulatory disclosure format for corporate actions, it is classified as a Regulatory Filing (RNS).
2023-12-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details the change in share ownership (specifically a reduction in holdings) by Rhinos Asset Management in Jinyang Pharm Co., Ltd. This type of filing is a standard regulatory requirement for significant shareholders to disclose changes in their equity positions, which falls under the 'Major Shareholding Notification' category.
2023-11-30 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the acquisition of convertible bonds (CB) before maturity by the issuing company, Jinyang Pharmaceutical. It details the specific bond series, acquisition amount, reason (call option exercise), and funding source. This falls under capital structure changes and financing activities, specifically related to debt management, which is best classified as a Capital/Financing Update (CAP).
2023-11-27 Korean
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the extension of a trust contract for the acquisition of treasury shares (자기주식취득 신탁계약 연장결정). This type of filing specifically details the company's decision to buy back its own shares or manage existing treasury share trust contracts. According to the provided definitions, reports concerning a company buying back or selling its own shares are classified as 'Transaction in Own Shares' (POS).
2023-11-17 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Jin Yang Pharmaceutical Co., Ltd. for the period ending September 30, 2023. It contains detailed financial information, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Jinyang Pharmaceutical regarding the adjustment of the conversion price of convertible bonds (CB). It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2023-08-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.